Skip to main content
logo
Cidara Therapeutics, Inc. (CDTX)
Jan 7, 2026 - CDTX was delisted (reason: acquired by MRK)
221.38
+0.06 (0.03%)
Inactive · Last trade price on Jan 6, 2026

Cidara Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
-1.2823.2864.2949.5712.07
Revenue Growth (YoY)
--94.52%-63.78%29.69%310.81%-42.30%
Gross Profit
-1.2823.2864.2949.5712.07
Selling, General & Admin
28.0920.6213.5818.4918.7415.9
Research & Development
131.82156.7636.7675.5273.0968.02
Total Operating Expenses
159.91177.3850.3494.0191.8383.92
Operating Income
-195.46-176.1-27.06-29.72-42.26-71.85
Interest Income
10.775.8120.19-0.21-0.26
Total Non-Operating Income (Expense)
10.775.8120.19-0.21-0.26
Pretax Income
-184.69-170.29-25.07-29.53-42.47-72.11
Provision for Income Taxes
--0.020.27--
Net Income
-184.74-169.83-22.93-29.8-42.47-72.11
Earnings From Discontinued Operations
0.060.462.15---
Net Income to Common
-184.74-169.83-22.93-29.8-42.47-72.11
Shares Outstanding (Basic)
1764332
Shares Outstanding (Diluted)
1764332
Shares Change (YoY)
229.09%45.26%25.15%33.18%26.22%38.83%
EPS (Basic)
-11.78-26.75-5.25-9.61-16.20-36.00
EPS (Diluted)
-11.78-26.75-5.25-9.61-16.20-36.00
Free Cash Flow
-132.94-176.66-22.94-28.59-25.27-54.6
Free Cash Flow Per Share
-8.02-27.82-5.25-8.19-9.64-26.28
Gross Margin
-100.00%100.00%100.00%100.00%100.00%
Operating Margin
--13811.92%-116.22%-46.23%-85.24%-595.42%
Profit Margin
--13356.16%-107.72%-46.35%-85.67%-597.59%
FCF Margin
--13855.84%-98.51%-44.47%-50.98%-452.45%
EBITDA
-195.33-175.87-26.94-29.58-42.07-71.56
EBITDA Margin
--13793.65%-115.72%-46.00%-84.86%-593.05%
EBIT
-195.46-176.1-27.06-29.72-42.26-71.85
EBIT Margin
--13811.92%-116.22%-46.23%-85.24%-595.42%
Effective Tax Rate
-0.00%-0.06%-0.92%0.00%0.00%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q